Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by Pandoraon Oct 14, 2021 1:45pm
238 Views
Post# 34006040

RE:RE:RE:The offering -- Sedar

RE:RE:RE:The offering -- Sedar
Last one from Sedar:




UNDERTAKING



Ontario Securities Commission
British Columbia Securities Commission
Alberta Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan

Re: Ventripoint Diagnostics Ltd. (the “Issuer”)
SEDAR Project No. 03282779
Final Short Form Prospectus dated October 13, 2021 under National
Instrument 44-101, Multilateral Instrument 11-102 and National Policy 11-
202


We refer to the Short Form Prospectus of Ventripoint Diagnostics Ltd. dated October 13, 2021
(the “Prospectus”) with respect to an offering of units of the Issuer.


The Issuer hereby undertakes, pursuant to subparagraph 4.2(a)(x) of National Instrument 44-101
Short Form Prospectus Distributions (“NI 44-101”), to file any agreement or contract referred to
in subparagraph 4.2(a)(iii) of NI 44-101 and any material contract under subparagraph
4.2(a)(iii.1) of NI 44-101 which has not been executed before the filing of the Prospectus, but will
be executed on or before the completion of the distribution of securities under the Prospectus,
promptly and in any event no later than seven days after the execution of the agreement, contract
or material contract.


The Issuer hereby undertakes, pursuant to subparagraph 4.2(a)(x.1) of NI 44-101, to file any
document referred to in subparagraph 4.2(a)(iii) of NI 44-101 which does not need to be executed
in order to become effective and has not become effective before the filing of the Prospectus but
will become effective on or before the completion of the distribution of securities under the
Prospectus, promptly and in any event no later than seven days after the document becomes
effective.


DATED this 13th day of October, 2021.


VENTRIPOINT DIAGNOSTICS LTD.


Per: “George Adams”
George Adams, CEO
<< Previous
Bullboard Posts
Next >>